In this context, Zhou and colleagues have demonstrated that melanoma patients with higher sPD-L1 levels at baseline had poorer outcome as compared to those patients with moderate/low sPD-L1 in response to ipilimumab-based therapy (38). The gene discussed is SPDL1; the disease is melanoma.